MIC-based therapies

Table of Contents

MIC-based therapies

MIC-based therapies

PK-PD principles of treatment

PK-PD principles of treatment

PPT Slide

Antibiotic resistance (%) of Streptococcus pneumoniae (Belgium)

PPT Slide

Optimizing dosage for beta-lactams

Amoxicillin dosage and resistance

Amoxicillin dosage and resistance

PK-PD levofloxacin and S. pneumoniae in Belgium

PK-PD levofloxacin and S. pneumoniae in Belgium

PK-PD moxifloxacin and S. pneumoniae in Belgium

Interpretive criteria for susceptibility testing (MIC:mg/L)

N. meningitidis: susceptibility data Belgium 1998 (n = 220)

S. pneumoniae cerebrospinal fluid isolates Belgium 1997-2000 (n=237)

S. pneumoniae cerebrospinal fluid isolates Belgium 1997-2000 (n = 237)

Pharmacokinetics in bacterial meningitis

Pharmacodynamics of beta-lactam antibiotics in bacterial meningitis

Clinical relevance of antibiotic resistance in bacterial meningitis

Clinical practice guideline for bacterial meningitis (Belgium)

MIC-based therapies: Infective Endocarditis

MIC-based therapies: other indications

PPT Slide

MIC-based therapies:Conceptual weaknesses (1)

MIC-based therapies:Conceptual weaknesses (2)

MIC-based therapies:Conceptual weaknesses (3)

MIC-based therapies:Conceptual weaknesses (4)

MIC-based therapies:Feasibility issues

MIC-based therapies:Conclusions

MIC-based therapies:Conclusions

MIC-based therapies:Conclusions

Email: webmaster@sbimc-bvikm.org

Home Page: http://www.sbimc-bvikm.org/sbimc-bvikm-slides.htm

Other information:
These slides are for information only. Do not make public use of them without the autorization of their author and of the SBIMC-BVIKM.

Download presentation as PDF file